Clinical perspectives of PSMA PET/MRI for prostate cancer
Prostate cancer imaging has become an important diagnostic modality for tumor evaluation. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has been extensively studied, and the results are robust and promising. The advent of the PET/magnetic resonance imaging (MRI) has ad...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier España
2018-09-01
|
| Series: | Clinics |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322018000200325&lng=en&tlng=en |
| _version_ | 1811226584733974528 |
|---|---|
| author | Felipe de Galiza Barbosa Marcelo Araújo Queiroz Rafael Fernandes Nunes José Flávio Gomes Marin Carlos Alberto Buchpiguel Giovanni Guido Cerri |
| author_facet | Felipe de Galiza Barbosa Marcelo Araújo Queiroz Rafael Fernandes Nunes José Flávio Gomes Marin Carlos Alberto Buchpiguel Giovanni Guido Cerri |
| author_sort | Felipe de Galiza Barbosa |
| collection | DOAJ |
| description | Prostate cancer imaging has become an important diagnostic modality for tumor evaluation. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has been extensively studied, and the results are robust and promising. The advent of the PET/magnetic resonance imaging (MRI) has added morphofunctional information from the standard of reference MRI to highly accurate molecular information from PET. Different PSMA ligands have been used for this purpose including 68gallium and 18fluorine-labeled PET probes, which have particular features including spatial resolution, imaging quality and tracer biodistribution. The use of PSMA PET imaging is well established for evaluating biochemical recurrence, even at low prostate-specific antigen (PSA) levels, but has also shown interesting applications for tumor detection, primary staging, assessment of therapeutic responses and treatment planning. This review will outline the potential role of PSMA PET/MRI for the clinical assessment of PCa. |
| first_indexed | 2024-04-12T09:27:35Z |
| format | Article |
| id | doaj.art-170ea510dfa348f7824720559b4ebdd4 |
| institution | Directory Open Access Journal |
| issn | 1980-5322 |
| language | English |
| last_indexed | 2024-04-12T09:27:35Z |
| publishDate | 2018-09-01 |
| publisher | Elsevier España |
| record_format | Article |
| series | Clinics |
| spelling | doaj.art-170ea510dfa348f7824720559b4ebdd42022-12-22T03:38:27ZengElsevier EspañaClinics1980-53222018-09-0173suppl 110.6061/clinics/2018/e586sS1807-59322018000200325Clinical perspectives of PSMA PET/MRI for prostate cancerFelipe de Galiza BarbosaMarcelo Araújo QueirozRafael Fernandes NunesJosé Flávio Gomes MarinCarlos Alberto BuchpiguelGiovanni Guido CerriProstate cancer imaging has become an important diagnostic modality for tumor evaluation. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has been extensively studied, and the results are robust and promising. The advent of the PET/magnetic resonance imaging (MRI) has added morphofunctional information from the standard of reference MRI to highly accurate molecular information from PET. Different PSMA ligands have been used for this purpose including 68gallium and 18fluorine-labeled PET probes, which have particular features including spatial resolution, imaging quality and tracer biodistribution. The use of PSMA PET imaging is well established for evaluating biochemical recurrence, even at low prostate-specific antigen (PSA) levels, but has also shown interesting applications for tumor detection, primary staging, assessment of therapeutic responses and treatment planning. This review will outline the potential role of PSMA PET/MRI for the clinical assessment of PCa.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322018000200325&lng=en&tlng=enProstate CancerPositron Emission Tomography/Magnetic Resonance ImagingDiagnostic ImagingTumor StagingLocal Neoplasm Recurrence |
| spellingShingle | Felipe de Galiza Barbosa Marcelo Araújo Queiroz Rafael Fernandes Nunes José Flávio Gomes Marin Carlos Alberto Buchpiguel Giovanni Guido Cerri Clinical perspectives of PSMA PET/MRI for prostate cancer Clinics Prostate Cancer Positron Emission Tomography/Magnetic Resonance Imaging Diagnostic Imaging Tumor Staging Local Neoplasm Recurrence |
| title | Clinical perspectives of PSMA PET/MRI for prostate cancer |
| title_full | Clinical perspectives of PSMA PET/MRI for prostate cancer |
| title_fullStr | Clinical perspectives of PSMA PET/MRI for prostate cancer |
| title_full_unstemmed | Clinical perspectives of PSMA PET/MRI for prostate cancer |
| title_short | Clinical perspectives of PSMA PET/MRI for prostate cancer |
| title_sort | clinical perspectives of psma pet mri for prostate cancer |
| topic | Prostate Cancer Positron Emission Tomography/Magnetic Resonance Imaging Diagnostic Imaging Tumor Staging Local Neoplasm Recurrence |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322018000200325&lng=en&tlng=en |
| work_keys_str_mv | AT felipedegalizabarbosa clinicalperspectivesofpsmapetmriforprostatecancer AT marceloaraujoqueiroz clinicalperspectivesofpsmapetmriforprostatecancer AT rafaelfernandesnunes clinicalperspectivesofpsmapetmriforprostatecancer AT joseflaviogomesmarin clinicalperspectivesofpsmapetmriforprostatecancer AT carlosalbertobuchpiguel clinicalperspectivesofpsmapetmriforprostatecancer AT giovanniguidocerri clinicalperspectivesofpsmapetmriforprostatecancer |